Fundies. English
Akari Therapeutics, Plc
EDGAR245 filing records in this dataset, filed from 2012-12-03 to 2026-10-30. Reported financial figures are available; chart coverage varies by period.
- Cash and cash equivalents
- 7.7 million USD Source
Exact value
7700000 USD
- Long-term debt including current maturities
- Not available
- Shares outstanding
- 140 billion shares Source
Exact value
140032769533 shares
Reported share-count change
114.68% · 74.8 billion shares
Year-over-year change in reported shares. Splits, issuance and buybacks can affect this figure; it does not isolate employee compensation or economic dilution.
Includes later revisions to earlier periods. Annual charts exclude incomplete years.
Latest filing recorded: 2026-10-30.
Financial data available through: 2025-12-31.
Coverage by financial measure
- revenue: No compatible figures in this window
- Operating income: 8 of 11 periods available· newest 2025-12-31
- Net income: 8 of 11 periods available· newest 2025-12-31
- Operating cash flow: 8 of 11 periods available· newest 2025-12-31
- Capital expenditure: 3 of 11 periods available· newest 2019-12-31
- Total assets: 8 of 11 periods available· newest 2025-12-31
- Total liabilities: 8 of 11 periods available· newest 2025-12-31
- Current assets: 8 of 11 periods available· newest 2025-12-31
- Current liabilities: 7 of 11 periods available· newest 2025-12-31
- Cash and cash equivalents: 8 of 11 periods available· newest 2025-12-31
- long term debt: No compatible figures in this window
- Shares outstanding: 8 of 11 periods available· newest 2025-12-31
Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.
What changed year over year
Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.
Net income
+USD 2.49 millionPrior period
−USD 19.79 million
–
Current period
−USD 17.3 million
–
Exact inputs and evidence
-17298000 − -19791000 = 2493000 USD
-19791000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source-17298000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current sourceShare or cite
The citation records this snapshot. The page link may show a newer release later.
Operating cash flow
+USD 1.98 millionPrior period
−USD 12.55 million
–
Current period
−USD 10.57 million
–
Exact inputs and evidence
-10568000 − -12552000 = 1984000 USD
-12552000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source-10568000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current sourceShare or cite
The citation records this snapshot. The page link may show a newer release later.
Comparable inputs unavailable for: Revenue, Capital expenditure.
Where revenue goes
How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.
Revenue is not reported for this company, so its costs cannot be shown as a share of it.
Growth
Sales over time and how quickly they are changing.
Revenue
Revenue reported for each complete financial period.
Values and sources
| Period | Series | Value | Source evidence |
|---|
Revenue growth
Change in revenue from the same financial period one year earlier.
Values and sources
| Period | Series | Value | Source evidence |
|---|
Profit and cash
How much revenue becomes profit, and how much cash operations generate.
Profit margins
Operating income, net income and free cash flow as a share of revenue.
- Operating margin
- Net margin
- Free cash flow margin
Values and sources
| Period | Series | Value | Source evidence |
|---|
Operating cash flow
Cash generated by the company’s normal business operations.
Values and sources
| Period | Series | Value | Source evidence |
|---|
Free cash flow
Operating cash flow minus capital expenditure for the same period and unit.
Values and sources
| Period | Series | Value(USD) | Source evidence |
|---|
Balance sheet
Liabilities and short-term ability to meet obligations at each period end.
Liabilities to assets
Total liabilities as a share of total assets.
Values and sources
| Period | Series | Value | Source evidence |
|---|
Current assets to current liabilities
Current assets divided by current liabilities.
Values and sources
| Period | Series | Value | Source evidence |
|---|
Cash generation
Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.
| Period | Net income | Operating cash flow | Capital expenditure | Free cash flow |
|---|---|---|---|---|
| 2015 2015-01-01 – 2015-12-31 | −USD 45.32 million Exact valueExact value: -45317532 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 4.97 million Exact valueExact value: -4965583 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | Unavailable Not reported for this period. | Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period. |
| 2016 2016-01-01 – 2016-12-31 | −USD 18.14 million Exact valueExact value: -18140997 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 24.62 million Exact valueExact value: -24624535 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | Unavailable Not reported for this period. | Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period. |
| 2017 2017-01-01 – 2017-12-31 | −USD 35.4 million Exact valueExact value: -35399257 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 31.6 million Exact valueExact value: -31598709 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | Unavailable Not reported for this period. | Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period. |
| 2018 2018-01-01 – 2018-12-31 | −USD 16.47 million Exact valueExact value: -16466780 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 22.58 million Exact valueExact value: -22580240 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | Unavailable Not reported for this period. | Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period. |
| 2022 2022-01-01 – 2022-12-31 | −USD 17.75 million Exact valueExact value: -17748000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 21.5 million Exact valueExact value: -21504000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | Unavailable Not reported for this period. | Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period. |
| 2023 2023-01-01 – 2023-12-31 | −USD 10.01 million Exact valueExact value: -10008000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 16.43 million Exact valueExact value: -16432000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | Unavailable Not reported for this period. | Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period. |
| 2024 2024-01-01 – 2024-12-31 | −USD 19.79 million Exact valueExact value: -19791000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 12.55 million Exact valueExact value: -12552000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | Unavailable Not reported for this period. | Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period. |
| 2025 2025-01-01 – 2025-12-31 | −USD 17.3 million Exact valueExact value: -17298000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 10.57 million Exact valueExact value: -10568000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | Unavailable Not reported for this period. | Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period. |
Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.
Dataset coverage and company identifiers
Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.
245 filings · 2,593 latest values · 2,593 originally reported values
Dataset published . Source filing dates and reporting periods are shown separately.
Identifiers: 0001541157, 1541157, AKTX, CLSXY, CLTX, edgar:1541157, mrrby
Also known as AKARI THERAPEUTICS PLC, AKARI THERAPEUTICS, PLC, Akari Therapeutics PLC, Akari Therapeutics Plc, Akari Therapeutics, PLC, Akari Therapeutics, Plc, Celsus Therapeutics Plc., Morria Biopharmaceuticals PLC